Equities research analysts predict that VBI Vaccines Inc (NASDAQ:VBIV) will announce sales of $970,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for VBI Vaccines’ earnings, with estimates ranging from $940,000.00 to $1.00 million. VBI Vaccines reported sales of $2.68 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 63.8%. The company is scheduled to report its next earnings report on Monday, February 24th.

According to Zacks, analysts expect that VBI Vaccines will report full-year sales of $2.60 million for the current fiscal year, with estimates ranging from $2.59 million to $2.60 million. For the next financial year, analysts expect that the company will post sales of $16.78 million, with estimates ranging from $5.25 million to $28.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million. VBI Vaccines had a negative net margin of 1,458.97% and a negative return on equity of 70.54%.

Several research firms have recently issued reports on VBIV. BidaskClub upgraded shares of VBI Vaccines from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Raymond James began coverage on shares of VBI Vaccines in a research report on Thursday, November 14th. They set an “outperform” rating and a $3.00 price objective on the stock. Finally, ValuEngine cut shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday, December 21st. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. VBI Vaccines presently has a consensus rating of “Buy” and a consensus target price of $3.81.

Several hedge funds have recently bought and sold shares of the stock. Wedbush Securities Inc. purchased a new position in shares of VBI Vaccines in the fourth quarter valued at $28,000. Squarepoint Ops LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $214,000. Sabby Management LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $413,000. Virtu Financial LLC purchased a new position in shares of VBI Vaccines in the third quarter valued at $122,000. Finally, State Street Corp grew its holdings in shares of VBI Vaccines by 4.3% in the third quarter. State Street Corp now owns 1,495,738 shares of the biopharmaceutical company’s stock valued at $705,000 after purchasing an additional 61,829 shares in the last quarter. 41.06% of the stock is owned by hedge funds and other institutional investors.

Shares of VBI Vaccines stock traded down $0.15 on Tuesday, hitting $1.63. 6,619,796 shares of the company traded hands, compared to its average volume of 7,811,935. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. VBI Vaccines has a 52 week low of $0.47 and a 52 week high of $2.20. The business has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $0.79.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Featured Story: Profit Margin

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.